Targeting the Wnt signaling pathway to treat Barrett's esophagus

Details

Serval ID
serval:BIB_0DD73208EE60
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Targeting the Wnt signaling pathway to treat Barrett's esophagus
Journal
Expert Opinion on Therapeutic Targets
Author(s)
Clement  G., Jablons  D. M., Benhattar  J.
ISSN
1744-7631 (Electronic)
Publication state
Published
Issued date
2007
Volume
11
Number
3
Pages
375-389
Notes
PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review
Abstract
Barrett's esophagus (BE) is an acquired condition in which the normal squamous epithelium in the distal esophagus is replaced by a metaplastic columnar epithelium, as a complication of chronic gastroesophageal reflux. The clinical significance of this disease is its associated predisposition to esophageal adenocarcinoma (EAC). Recently, and similarly to other human malignancies, the Wnt signaling pathway and its key component beta-catenin have been implicated in the carcinogenesis of BE. Although mutations in adenomatous polyposis coli (APC) or beta-catenin are rare in EAC, alterations of upstream components, such as overexpression of Wnt2 ligand or downregulation of Wnt antagonists may play dominant roles in the activation of the Wnt pathway. Increasing evidence suggests that inhibiting the Wnt pathway may be a new targeted therapy for the treatment of cancers and could, therefore, be promising for the cure of EAC, which remains a highly lethal disease
Keywords
Adenocarcinoma/drug therapy/etiology/metabolism/Animals/Antineoplastic Agents/therapeutic use/Barrett Esophagus/complications/Esophageal Neoplasms/Humans/Wnt Proteins/antagonists & inhibitors
Pubmed
Web of science
Create date
29/01/2008 18:34
Last modification date
20/08/2019 12:34
Usage data